A patient having their blood pressure measured by a doctor

Familial Hypercholesterolaemia

Familial Hypercholesterolaemia (FH) is a common genetic disorder leading to lifelong elevations in LDL-Cholesterol, high cardiovascular risk and development of premature cardiovascular disease. Despite its frequency and preventable outcomes, FH is largely underdiagnosed and undertreated, and represents an unaddressed major public health problem.

The European Atherosclerosis Society (EAS) FH Studies Collaboration (EAS FHSC) is an international collaboration of investigators with an interest in FH. The mission of the EAS FHSC aims to empower the medical and global community to seek changes in their respective countries or organizations regarding how FH is detected, managed, and the clinical consequences thereof, with a view to promoting early diagnosis and more effective treatment of FH.

The EAS FHSC Coordinating Centre is based in the Imperial Centre for Cardiovascular Disease Prevention (ICCP) at Imperial College London. The EAS FHSC global network of investigators and registry will permit the generation of robust large-scale information on how FH is detected and managed, and the clinical consequences of current practices on outcomes. The information generated will help close gaps in knowledge, inform about the best interventions, account for providing effective and efficient care, and consequently support the best evidence-based decision making in FH.

For more information visit the EAS FH Studies Collaboration.
Funders: EAS, MSD, Sanofi and Amgen

Clinical trials

The ICCP under Professor Ray participates on the Steering Committee, Executive Committee or as the Principal Lead Investigator of global phase 2 and 3 trials in the areas of dyslipidaemia, diabetes, and cardiovascular risk reduction. ICCP partners with multinational pharmaceutical companies, biotech firms and leading academic centres around the world to test novel therapies to reduce the burden of cardiovascular disease.

Learn more about the various clinical trials we are involved in.


The UKWHS was initially designed in the 1980s as a cross sectional study by Imperial College London and later in partnership with the University of Manchester. Approximately 21 000 women aged 30-60 years had baseline demographic data and lifestyle information collected together with physical measurements as well as stored blood samples for biomarker and genetic analyses.

Currently, we plan to link the baseline data to fatal and non-fatal cardiovascular events which should allow for 400 000 person years of exposure and report on a 1-2000 cases of cardiovascular disease. This will provide information on the largest prospective cohort of British Women from all regions of the Great Britain and Ireland. Following these initial data, blood and genetic material will be analysed for discovery and personalised medicine.

Funder: Sanofi